Cannabis Law Report

JANUARY 31, 2022

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Earlier this month, Health Canada added certain psychedelic compounds to the SAP that were previously available only through clinical trials. investment community.”

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Guy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

The Cannigma

FEBRUARY 2, 2021

Patients can also access CBD products without a prescription through local pharmacies. Our data confirm that PD patients have a high interest in treatment with medicinal cannabis but lacked knowledge about how to take it and especially the differences between the two main cannabinoids, THC and CBD,” said Buhmann.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

SEPTEMBER 12, 2022

The Company is working to supply various upcoming phase 1 & 2 clinical trials to build out the required human safety data in healthy Canadians, and eventually patients suffering from depression, anxiety, and PTSD. To access a complete photo gallery of this historic grow, please click here. Penis Envy.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

JULY 28, 2021

MAPS PBC strives to continually improve upon the supportive, equitable and accessible work environment. QC study data output files and raw datasets into data tables for regulatory documents as needed. 2-3 years of relevant experience in clinical trials, research methods, or statistical design and analysis.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

JULY 30, 2019

Cannabis-based products will be allowed to bypass usual processes required for medicines in New Zealand and go directly onto the market without any proof of safety or effectiveness. This unprecedented proposal is contained in the government’s consultation document on giving greater access to medicinal cannabis.

Medicine 40

Medicine Clinical Trials Safety Access 40

Cannabis Law Report

SEPTEMBER 20, 2021

provides Heritage and subsidiary Opticann the benefits of offering patients access to safe, convenient, and effective CB4 products developed on trusted technology platforms. The products leverage pharmaceutical technology to maximize performance and safety. TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. Drug Enforcement Agency (DEA). federal law.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Clinical Trials and Human Subject Protections. Here are the top five considerations: 1.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JANUARY 13, 2020

commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Veriheal

AUGUST 31, 2020

Data shows that Hispanic Americans are more interested in using cannabis and CBD for wellness than other groups and “is believed to be in part due to the connections between the Hispanic community and nature.” Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

DECEMBER 2, 2021

Safety, Ethics and Responsibilities of a Psilocybin Facilitator (10 Hours). Psilocybin Pharmacology, Neuroscience, and Clinical Research (12 Hours). Programs shall train students on how to proactively make psilocybin services accessible to people with disabilities. Core Psilocybin Facilitation Skills (16 Hours). info@gl-lg.com

Law 52

Law Programs Therapy Education 52

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Available at: [link] Accessed 05 Dec. link] -Accessed December 5, 2021.

Patients 98

Patients Education Marijuana Therapy 98

The Cannigma

JUNE 15, 2021

However, the scientific data on CBG is nowhere near as developed as what we have on CBD. For now, if you have access to quality CBD products, there’s no reason to prioritize CBG products. Easy access. But the main issue with hemp derived products and their safety is less about the CBD and more about everything else in them.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. Prior to joining Sesen Bio, Mr. Barbera served as the Vice President of Market Access at UroGen Pharma and played a critical role in the launch of the company’s first commercial product, Jelmyto ®. Sesen Bio remains committed to the health and safety of patients, caregivers and employees.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

SEPTEMBER 24, 2019

We believe patients and physicians deserve access to rigorously tested and evaluated cannabis-based medicines, manufactured to the highest standards and approved by medicines regulators, and we are delighted to be the first to offer this solution to the epilepsy community.”.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Accessed July 25, 2021. Available at: [link] Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Canna Law Blog

NOVEMBER 6, 2021

To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. But only if it is made affordable and accessible.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

MAY 1, 2022

We note nearly half (49%) of the respondents to your Community Interest Survey indicated that their interest in accessing psilocybin under Measure 109 was for spiritual purposes. The addition of the word “including” suggests that public health and safety are two examples of the goals of sections 3 to 129 rather than an exhaustive list.

Safety 52

Safety History Programs Clinical Trials 52

The Cannigma

JANUARY 13, 2023

A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. Topical cannabis products can also be useful, but research and data is very limited.

Terpenes 132

Terpenes Strains THC Treatment 132

The Cannigma

APRIL 8, 2021

The Cannabis Enigma is a co-production of The Cannigma and Americans for Safe Access. You definitely deserve access to talk to someone like me. CP: I’m going to say yes and it’s hard to tie this together, but there’s actually some really good animal, and a little bit of human data to support this. Music by Desca. MSO: I agree.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

MAY 13, 2019

In nearly every jurisdiction where medicinal cannabis is legal, at least one medical professional is required to sign off for a person to access it. The number of jurisdictions allowing access to medicinal cannabis has been steadily increasing since the state of California introduced legislation in 1996. Gardiner , Judith A.

Medicine 45

Medicine Research and Development Clinical Trials Data 45

The Cannigma

FEBRUARY 1, 2023

Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. Use harm reduction techniques (i.e.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety 45

Safety CBD Clinical Trials Oil 45

Cannabis Law Report

AUGUST 30, 2019

The US Department of Agriculture (USDA) has released new data indicating a substantial increase in the growth of US hemp production. The campaign is designed to remind citizens that while cannabis use is now legal, operating vehicles while under its influence remains against the law and is a public safety issue. Medical/Health.

Banking 45

Banking Research and Development Legislation Programs 45

The Cannigma

DECEMBER 22, 2021

Listen & Subscribe: Israel is world-renowned for the research and innovation that is taking place there, and unofficial data suggests that around 20% of the Israeli population uses cannabis. The Cannabis Enigma is a co-production of The Cannigma and Americans for Safe Access. Music by Desca. I won’t do too many spoilers here.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Cannabis Law Report

DECEMBER 7, 2021

Our audacious mission is to create the new standard of trust and transparency consumers deserve and healthcare providers demand on these widely accessible potential therapies. The large scale and intentional heterogeneity of our studies can transform these consumer health products into democratized precision solutions.”.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

JULY 21, 2022

The comprehensive legislation would end federal cannabis prohibition by removing cannabis from the Controlled Substances Act; empower states to create their own cannabis laws; ensure federal regulation protects public health and safety; and prioritize restorative and economic justice .

Safety 52

Safety Legislation Clinical Trials Banking 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. Jonathan is the CEO and founder of Gilgamesh Pharmaceuticals. in/jonathan-sporn-4ba7802/ [link].

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

OCTOBER 17, 2019

Another researcher, New Frontier Data, pegged the global value of legal and illicit cannabis together at $340 billion in 2018. Many of these are meant to address public safety risks, especially for young people. billion in 2018, and with a compound annual growth rate of 23.9%, is predicted to reach $66.3

Law 40

Law Seed-To-Sale Hemp Recreational 40